Journal
SURGERY TODAY
Volume 50, Issue 4, Pages 335-343Publisher
SPRINGER
DOI: 10.1007/s00595-020-01963-2
Keywords
Pancreatic ductal adenocarcinoma; Multimodality treatment; Borderline resectable
Categories
Ask authors/readers for more resources
A multimodal approach to treating pancreatic ductal adenocarcinoma (PDAC) is now widely accepted. Improvements in radiological assessment have enabled us to define resectability in detail. Multimodality treatment is essential for patients, especially for those with PDAC in the borderline resectable (BR) stage. Even for disease in a resectable (R) stage, adjuvant and neoadjuvant therapies have demonstrated beneficial outcomes in several trials and analyses. Thus, there is growing interest in optimization of the perioperative therapeutic strategy. We discuss the transition of resectability criteria and the global standard of adjuvant and neoadjuvant treatments for patients with R/BR-PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available